查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1999447

糖尿病相關眼科治療市場：依治療方法、給藥途徑、患者類型及最終用戶分類－2026-2032年全球市場預測

Diabetes Associated Ophthalmic Treatment Market by Treatment Type, Route Of Administration, Patient Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，糖尿病相關眼科治療市場價值將達到 67.4 億美元，到 2026 年將成長至 73.6 億美元，到 2032 年將達到 132.3 億美元，複合年成長率為 10.09%。

主要市場統計數據
基準年 2025 67.4億美元
預計年份：2026年 73.6億美元
預測年份 2032 132.3億美元
複合年成長率 (%) 10.09%

簡要概述影響糖尿病相關眼科治療和醫療保健服務模式的臨床複雜性和策略考量。

糖尿病相關眼科疾病在臨床和商業性都面臨著複雜的挑戰，涉及慢性病管理、先進的生物製藥療法以及不斷發展的醫療服務模式。本報告整合了糖尿病患者眼科治療的臨床過程、新治療方法以及相關人員，旨在整體情況。其目標是提供清晰、以醫療保健為導向的指南，將科學進展與治療方法引入、獲取和患者預後等方面的實際考慮聯繫起來。

治療創新、精準診斷和醫療保健服務體系的重新設計如何共同重新定義糖尿病眼科疾病的治療路徑和運作模式。

糖尿病眼科疾病的眼科治療正經歷一場變革，這場變革的驅動力來自治療創新、數位醫療的融合以及不斷發展的給藥平台。過去幾年，針對血管內皮生長因子 (VEGF) 及其相關路徑的生物製藥重新定義了標準治療方案，而長效製劑和植入式給藥系統則為治療的連續性和臨床工作流程引入了新的模式。因此，臨床醫生能夠更有效地平衡療效與減少就診次數之間的關係，這反過來又改變了臨床資源的分配方式以及病患監測的優先順序。

了解 2025 年關稅措施對供應鏈和眼科護理取得的連鎖營運、採購和策略影響。

2025年起對部分進口藥品、醫療設備及相關組件徵收關稅，將對眼科醫療保健產業的整個供應鏈、採購慣例和定價策略產生累積影響。生物製藥、植入式給藥系統和專用醫療設備的採購週期將受到直接衝擊。到岸成本的增加將迫使醫療系統和付款方重新評估其採購方案。這將導致高需求治療方法的短期供應中斷，同時，製造商將更有獎勵加快區域生產並調整供應路線，以減輕關稅的影響。

綜合細分分析揭示了治療方法、給藥途徑、患者人口統計特徵和醫療保健環境如何共同決定臨床和商業性路徑。

詳細的細分分析揭示了治療方法、給藥途徑、患者人口統計特徵和醫療環境如何相互作用並影響臨床實踐和商業策略。就治療方法類型而言，抗VEGF療法仍然是臨床管理的核心，阿柏西普、Bevacizumab、布羅盧西珠單抗、法利西單抗和雷珠單抗等藥物各自具有不同的療效、給藥間隔和安全性，有助於治療方法的選擇。對於患有發炎性水腫或對抗VEGF療法反應不佳的患者，皮質類固醇（如地塞米松植入劑、氟輕鬆植入劑和曲安奈德）是重要的替代療法，其緩釋特性可以改變監測頻率並提高臨床效率。雷射療法，例如聚焦/網格狀光凝固術和全視網膜光凝術，在某些疾病階段繼續發揮作用，作為藥物治療的補充。

區域間在基礎設施、管理體制和准入優先事項方面的差異，對糖尿病眼科疾病治療方法的引入途徑產生了決定性的影響。

區域特徵顯著影響糖尿病相關眼科治療方法的研發、推廣和報銷，三大主要區域各有不同的促進因素。在美洲，先進的臨床基礎設施、強大的眼科專家網路和相對完善的支付機制支援新型生物製藥和緩釋植入的快速應用。然而，都市區之間的醫療服務可近性仍然存在差距，綜合醫療網路和採購聯盟的採購趨勢也會影響處方藥清單和治療方法的可近性。

臨床創新、生產規模和數位診斷的策略能力如何決定眼科治療領域相關人員之間的競爭地位？

在眼科治療生態系統中運作的產業相關人員，其臨床創新、可擴展生產和穩健的商業性可行性整合能力日益凸顯，從而形成差異化競爭格局。專注於生物製劑和長效藥物的領先製藥和生物技術開發公司，正大力投資於臨床開發項目和真實世界數據（REW）收集，以證明其療效的持續性並確立高階市場地位。同時，緩釋植入和手術器械的製造商則致力於提高給藥可靠性並減輕醫療機構的負擔，這推動了高流量手術中心和專科診所對這些產品的採用。

為相關人員提供實用策略指南，以協調糖尿病眼科疾病管理中的臨床創新、供應彈性和支付方合作。

產業領導企業應採取多管齊下的策略，兼顧臨床價值、供應韌性和與支付方的合作，以維持成長並改善患者療效。首先，持續投資於差異化治療方案，例如新型分子標靶、緩釋製劑或可減少就診次數的給藥系統，將有助於提高其在臨床實踐中的應用，並滿足真實臨床環境中尚未滿足的需求。同時，增加對嚴謹證據的投入，包括進行可操作性研究和建立註冊登記系統，對於證明療效的相對可比性以及推動醫保報銷方面的討論至關重要。

嚴謹的混合方法研究框架，結合專家訪談、臨床文獻整合和透過三角測量進行資料檢驗，以支持實務見解。

本研究採用混合方法，將主要質性研究結果與全面的二手資料檢驗，以得出可靠且可操作的結論。主要研究包括對臨床意見領袖、醫院採購負責人、專科診所管理人員和保險公司代表進行結構化訪談，以了解實際運作、處方決定因素和就醫障礙。這些相關人員訪談用於將臨床試驗證據置於具體情境中，並檢驗關於醫療服務動態和物流限制的假設。

一份簡明扼要、全面全面的分析報告，重點闡述了臨床進步、供應韌性和相關人員合作將如何決定糖尿病眼科疾病護理的未來可及性和結果。

總而言之，糖尿病相關眼科疾病的管理正進入一個更精細、以能力主導的階段，治療方法、診斷準確性和交付模式的融合將重塑診療路徑。價值鏈上的相關人員面臨著如何將產品差異化與營運可行性、支付方期望以及以患者為中心的服務模式相協調的挑戰。隨著新型生物製藥、緩釋技術和數位診斷技術的日益成熟，成功的關鍵在於展現其在真實世界中的臨床獲益，同時確保供應鏈的穩健性和公平的獲取途徑。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依治療方法分類的糖尿病相關眼科治療市場

  • 抗 VEGF
    • 阿柏西普
    • Bevacizumab
    • 布羅盧西珠單抗
    • 法利西單抗
    • 雷尼珠單抗
  • 皮質類固醇
    • 地塞米松植入劑
    • 氟輕鬆植入物
    • 曲安奈德
  • 雷射治療
    • 局部/網格光凝
    • 全視網膜光凝固術
  • 手術介入

第9章：糖尿病相關眼科治療市場：依給藥途徑分類

  • 玻璃體內注射
    • 預填充式注射器
    • 管瓶
  • 全身給藥
    • 靜脈
    • 口服
  • 局部的
    • 眼藥水
    • 軟膏

第10章：依病患類型分類的糖尿病相關眼科治療市場

  • 1型糖尿病
  • 2型糖尿病

第11章：糖尿病相關眼科治療市場：依最終使用者分類

  • 門診手術中心
  • 醫院
  • 眼科診所
  • 零售藥房

第12章：糖尿病相關眼科治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：糖尿病相關眼科治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 糖尿病相關眼科治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國糖尿病相關眼科治療市場

第16章：中國糖尿病相關眼科治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Adverum Biotechnologies, Inc.
  • Aerpio Therapeutics, Inc.
  • Alimera Sciences, Inc.
  • Apexian Pharmaceuticals, Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Glycadia Pharmaceuticals, Inc.
  • Kodiak Sciences Inc.
  • Kubota Vision, Inc.
  • MingSight Pharmaceuticals, Inc.
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • Oxurion NV
  • Regeneron Pharmaceuticals, Inc.
  • Regenxbio Inc.
  • RemeGen Co., Ltd.
  • Santen Pharmaceutical Co., Ltd.
Product Code: MRR-563BF1FCF469

The Diabetes Associated Ophthalmic Treatment Market was valued at USD 6.74 billion in 2025 and is projected to grow to USD 7.36 billion in 2026, with a CAGR of 10.09%, reaching USD 13.23 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.74 billion
Estimated Year [2026] USD 7.36 billion
Forecast Year [2032] USD 13.23 billion
CAGR (%) 10.09%

A concise orientation to the clinical complexity and strategic considerations shaping diabetes-related ophthalmic therapies and care delivery models

Diabetes-associated eye disease presents a complex clinical and commercial challenge that intersects chronic disease management, advanced biologic therapies, and evolving care delivery models. This report introduces the therapeutic landscape by synthesizing clinical trajectories, emerging treatment modalities, and stakeholder priorities that shape how ophthalmic care for people with diabetes is delivered. The objective is to provide a clear, practitioner-focused orientation that links scientific advancement with practical considerations for therapy adoption, access, and patient outcomes.

Beginning with the clinical context, the narrative emphasizes how retinal vascular pathology, macular edema, and proliferative retinopathy drive vision impairment in both type 1 and type 2 diabetes populations. Treatment paradigms have shifted from primarily destructive laser approaches to pharmacologic modulation of pathogenic pathways, requiring new competencies among ophthalmology teams and novel supply chain arrangements for biologics and implantable devices. Consequently, clinicians, payers, and manufacturers must navigate a landscape where efficacy, safety, administration convenience, and total cost of care are balanced simultaneously.

The introduction frames subsequent sections by highlighting the interplay between technological innovation, regulatory strategy, and evolving care settings. It underscores the need for integrated evidence generation, from randomized trials to real-world studies, to support clinical decision-making and reimbursement. Through this lens, the report positions readers to understand not only what therapies exist, but how market dynamics and health-system constraints will influence clinical adoption and patient access in the near to mid term.

How therapeutic innovation, precision diagnostics, and care delivery redesign are jointly redefining treatment pathways and operational models in diabetic eye disease

The ophthalmic treatment landscape for diabetic eye disease is undergoing transformative shifts driven by therapeutic innovation, digital health integration, and evolving delivery platforms. Over the past several years, biologic agents targeting vascular endothelial growth factor and complementary pathways have redefined standard of care, while longer-acting formulations and implantable delivery systems have introduced new paradigms for treatment persistence and clinic workflow. As a result, clinicians are increasingly able to balance efficacy with reduced visit frequency, which alters how practices allocate clinical capacity and prioritize patient monitoring.

Simultaneously, diagnostic precision has improved through the adoption of advanced retinal imaging and artificial intelligence-enabled interpretation, enabling earlier detection and stratification of disease. These technology-driven advances facilitate more personalized treatment regimens and support outcome tracking across diverse care settings, from specialized ophthalmology clinics to ambulatory surgical centers. The expansion of ambulatory and outpatient procedural capacity has amplified the importance of streamlined administration formats, such as prefilled syringes and sustained-release implants, that reduce procedural complexity and improve patient throughput.

Regulatory and payer landscapes are adapting to these innovations by increasingly emphasizing real-world evidence and health economic data to assess value. Innovators and incumbents are responding with strategic partnerships, lifecycle management programs, and novel commercial models designed to demonstrate meaningful improvements in functional vision and health-related quality of life. Collectively, these forces are reshaping how therapies are developed, reimbursed, and delivered, signaling a move toward more integrated, patient-centric ophthalmic care.

Understanding the cascading operational, procurement, and strategic consequences of 2025 tariff measures on ophthalmic therapy supply chains and access

The implementation of tariffs targeting certain imported pharmaceuticals, medical devices, and related components in 2025 exerts a cumulative influence across supply chains, procurement practices, and pricing strategies in ophthalmic care. Immediate effects are seen in procurement cycles for biologic agents, implantable delivery systems, and specialized instrumentation, where increased landed costs prompt health systems and payers to reassess sourcing options. This, in turn, can create short-term disruptions in availability for high-demand therapies while incentivizing manufacturers to accelerate regional manufacturing or to reconfigure supply routes to mitigate tariff exposure.

Over time, the tariff environment encourages a strategic shift toward localized production and diversified supplier networks. Contract manufacturers and device assemblers with regional capabilities become more attractive partners, and long-term sourcing agreements are restructured to lock in more favorable terms. Clinicians and administrators may encounter changes in formulary composition as hospital purchasing groups and clinics seek alternatives that preserve clinical effectiveness while managing budget impacts. For drugs where therapeutic alternatives exist, this dynamic can prompt increased adoption of biosimilars or different delivery formats that offer cost or logistic advantages.

Crucially, tariffs also influence investment decisions for clinical development and manufacturing expansion. Companies contemplating capital deployment may prioritize investments that reduce exposure to cross-border trade vulnerabilities, such as onshore fill-finish capacity or regional packaging. From a payer and policymaker perspective, the tariff-driven landscape heightens the importance of robust health technology assessments and procurement transparency to safeguard patient access while maintaining fiscal discipline. Stakeholders who proactively adapt contracting, clinical logistics, and sourcing strategies will be better positioned to manage the operational consequences of the 2025 tariff environment.

An integrated segmentation view revealing how treatment modality, administration route, patient population, and care setting jointly determine clinical and commercial pathways

A granular segmentation analysis clarifies how treatment modalities, administration routes, patient populations, and care settings interact to influence clinical practice and commercial strategy. When treatments are considered by type, anti-VEGF therapies remain central to clinical management, with agents such as aflibercept, bevacizumab, brolucizumab, faricimab, and ranibizumab each offering distinct efficacy, dosing interval, and safety profiles that inform therapy selection. Corticosteroid options, including dexamethasone implant, fluocinolone implant, and triamcinolone, provide important alternatives for patients with inflammation-driven edema or those who respond inadequately to anti-VEGF, and their sustained-release characteristics alter monitoring cadence and clinic throughput. Laser therapy, represented by focal/grid photocoagulation and panretinal photocoagulation, continues to play a role in specific disease stages and complements pharmacologic approaches.

Route of administration is a defining commercial variable because intravitreal injection remains the predominant delivery pathway, and nuances such as the availability of prefilled syringe formats versus vial presentations affect clinic efficiency, patient comfort, and safety protocols. Systemic options delivered intravenously or orally are less common but remain relevant for particular indications and comorbidities, while topical formulations delivered as eye drops or ointments may support adjunctive care or early-stage interventions. Patient type delineation between type 1 diabetes and type 2 diabetes is clinically meaningful because disease trajectories, comorbidity profiles, and treatment engagement differ, influencing adherence patterns and follow-up needs.

End user segmentation across ambulatory surgical centers, hospitals, ophthalmology clinics, and retail pharmacies shapes how therapies are accessed and administered. Ambulatory surgical centers and specialized clinics often optimize for procedures requiring intravitreal administration or implant placement, whereas hospitals handle higher-acuity cases and complex comorbid management. Retail pharmacies play a critical role in dispensing systemic and topical therapies and are increasingly involved in patient support programs. Understanding the interplay among these segments enables stakeholders to design targeted value propositions, optimize distribution channels, and align clinical support services with the operational realities of each care setting.

Regional contrasts in infrastructure, regulatory regimes, and access priorities that decisively influence adoption pathways for diabetic ophthalmic therapies

Regional characteristics substantially influence how diabetes-related ophthalmic therapies are developed, adopted, and reimbursed, and three macro regions demonstrate distinct drivers. In the Americas, advanced clinical infrastructure, prominent specialty ophthalmology networks, and relatively well-established payer mechanisms support rapid uptake of novel biologics and sustained-release implants. However, access disparities persist across urban and rural settings, and procurement dynamics among integrated delivery networks and purchasing coalitions shape formulary decisions and therapy availability.

Europe, the Middle East, and Africa present a heterogeneous landscape where regulatory frameworks and reimbursement pathways vary significantly. In parts of Europe, centralized health technology assessment processes and strong emphasis on real-world effectiveness guide adoption, whereas markets in the Middle East and select African countries may experience more variability in availability and pricing. Across this broad region, cross-border procurement, regional manufacturing hubs, and public-private partnerships play pivotal roles in ensuring consistent access to advanced ophthalmic care.

Asia-Pacific is characterized by rapid innovation adoption in urban centers, a growing base of local manufacturers, and diverse payer models that range from national insurance schemes to out-of-pocket dominant systems. The region's large diabetic population and evolving specialty care capacity make it a focal point for clinical trials, manufacturing scale-up, and differentiated pricing strategies. Across all regions, logistical factors, regulatory timelines, and health-system priorities dictate how quickly new treatments transition from approval to routine clinical use, and regional strategies must be tailored to reflect these contextual realities.

How strategic capabilities in clinical innovation, manufacturing scale, and digital diagnostics determine competitive positioning among ophthalmic therapy stakeholders

Industry participants operating in the ophthalmic treatment ecosystem are increasingly differentiated by their ability to integrate clinical innovation with scalable manufacturing and robust commercial execution. Leading pharmaceutical and biotechnology developers that focus on biologics and long-acting agents invest heavily in clinical development programs and real-world evidence generation to demonstrate durable outcomes and support premium positioning. At the same time, manufacturers of sustained-release implants and procedural devices concentrate on improving delivery reliability and minimizing clinic burden, which enhances adoption among high-volume surgical centers and specialty practices.

Generic and biosimilar producers are strategically positioned to capture demand for lower-cost alternatives, particularly where payers prioritize cost containment. These entrants typically emphasize manufacturing efficiency, regulatory expediency, and targeted contracting to gain formulary inclusion. Meanwhile, diagnostic and digital health companies offering advanced retinal imaging or artificial intelligence tools are strengthening value propositions for early detection and treatment monitoring, thereby creating synergies with therapeutic providers seeking to demonstrate improved outcomes and optimized care pathways.

Commercial strategies among these diverse players often include partnerships with contract manufacturers, alliances with clinical networks for data generation, and coordinated patient support programs to enhance adherence. Firms that combine therapeutic differentiation with operational excellence in supply chain, regulatory navigation, and stakeholder engagement are better positioned to influence prescribing patterns and secure favorable contract terms with institutions and payers.

A pragmatic strategic playbook for stakeholders to align clinical innovation, supply resilience, and payer engagement in diabetic eye disease management

Industry leaders should pursue a multifaceted strategy that addresses clinical value, supply resilience, and payer alignment to sustain growth and improve patient outcomes. First, continuing to invest in differentiated therapeutic profiles-whether through novel molecular targets, extended-duration formulations, or delivery systems that reduce clinic visit frequency-will strengthen clinical adoption and address unmet needs in real-world practice. Parallel investment in rigorous evidence generation, including pragmatic studies and registries, is essential to demonstrate comparative effectiveness and support reimbursement dialogues.

Second, supply chain diversification and regional manufacturing partnerships will mitigate exposure to cross-border trade volatility and tariff-induced cost pressures. Establishing flexible sourcing arrangements, investing in onshore or nearshore fill-finish capabilities, and negotiating long-term contracts with critical suppliers will preserve access and stabilize procurement costs. Third, engaging payers and health systems early with transparent value propositions and outcomes-based contracting pilots can align incentives around functional vision improvements and total cost of care, increasing the likelihood of favorable formulary placement.

Finally, enhancing patient support and adherence programs, integrating digital monitoring tools, and strengthening collaborations with ambulatory surgical centers and ophthalmology clinics will optimize administration workflows and patient experience. By implementing these coordinated actions, industry leaders can navigate regulatory complexity, secure sustainable commercial pathways, and ultimately expand timely access to sight-preserving therapies for people living with diabetes.

A rigorous mixed-methods research framework combining expert interviews, clinical literature synthesis, and triangulated data validation to underpin actionable insights

This research employs a mixed-methods approach that triangulates primary qualitative insights with comprehensive secondary data to ensure robust, actionable conclusions. Primary research includes structured interviews with clinical thought leaders, hospital procurement officers, specialty clinic administrators, and payer representatives to capture operational realities, prescribing drivers, and access barriers. These stakeholder interviews are used to contextualize clinical trial evidence and to validate assumptions about care delivery dynamics and logistical constraints.

Secondary research sources include peer-reviewed clinical literature, regulatory filings, device approvals, and clinical trial registries to map therapeutic mechanisms, safety profiles, and trial endpoints. In addition, public health reports and guidelines from recognized health authorities provide the clinical practice context and inform discussions about standard-of-care approaches. Data synthesis involves cross-referencing multiple information streams to reconcile discrepancies and to derive nuanced insights about adoption barriers, administrative burden, and practical considerations for treatment deployment.

Analytical rigor is maintained through systematic data coding, thematic analysis of qualitative interviews, and iterative validation with subject-matter experts. Limitations are acknowledged, including variability in regional reporting practices and the dynamic nature of clinical development pipelines. Where gaps exist, the methodology prioritizes transparency about evidence sources and the degree of expert consensus informing key conclusions.

A concise synthesis highlighting how clinical advances, supply resilience, and stakeholder alignment will determine future access and outcomes in diabetic eye care

In summary, the management of diabetes-associated ophthalmic disease is entering a more nuanced and capability-driven phase, where therapeutic innovation, diagnostic precision, and delivery model evolution converge to reshape care pathways. Stakeholders across the value chain face the imperative of aligning product differentiation with operational feasibility, payer expectations, and patient-centered service models. As novel biologics, sustained-release technologies, and digital diagnostics mature, success will hinge on the ability to demonstrate real-world benefit while ensuring supply chain robustness and equitable access.

Operationally, the combined pressures of tariff-driven procurement shifts and the need for localized manufacturing capacity underscore the importance of proactive supply strategies. Clinically, the diversity of treatment options and administration routes requires tailored protocols that reflect patient type, comorbidity burden, and care setting capabilities. From a commercial perspective, differentiation will come from integrated offerings that link therapeutic efficacy with demonstrable improvements in care efficiency and patient experience.

For policymakers and payers, the evolving evidence base calls for adaptive assessment frameworks that value long-term functional outcomes and incentivize adherence-supporting innovations. Ultimately, a collaborative approach among manufacturers, clinicians, payers, and providers will be essential to translate technological progress into sustained reductions in vision loss attributable to diabetes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Diabetes Associated Ophthalmic Treatment Market, by Treatment Type

  • 8.1. Anti-VEGF
    • 8.1.1. Aflibercept
    • 8.1.2. Bevacizumab
    • 8.1.3. Brolucizumab
    • 8.1.4. Faricimab
    • 8.1.5. Ranibizumab
  • 8.2. Corticosteroids
    • 8.2.1. Dexamethasone Implant
    • 8.2.2. Fluocinolone Implant
    • 8.2.3. Triamcinolone
  • 8.3. Laser Therapy
    • 8.3.1. Focal/Grid Photocoagulation
    • 8.3.2. Panretinal Photocoagulation
  • 8.4. Surgical Intervention

9. Diabetes Associated Ophthalmic Treatment Market, by Route Of Administration

  • 9.1. Intravitreal Injection
    • 9.1.1. Prefilled Syringe
    • 9.1.2. Vial
  • 9.2. Systemic
    • 9.2.1. Intravenous
    • 9.2.2. Oral
  • 9.3. Topical
    • 9.3.1. Eye Drops
    • 9.3.2. Ointments

10. Diabetes Associated Ophthalmic Treatment Market, by Patient Type

  • 10.1. Type 1 Diabetes
  • 10.2. Type 2 Diabetes

11. Diabetes Associated Ophthalmic Treatment Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Ophthalmology Clinics
  • 11.4. Retail Pharmacies

12. Diabetes Associated Ophthalmic Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Diabetes Associated Ophthalmic Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Diabetes Associated Ophthalmic Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Diabetes Associated Ophthalmic Treatment Market

16. China Diabetes Associated Ophthalmic Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Adverum Biotechnologies, Inc.
  • 17.6. Aerpio Therapeutics, Inc.
  • 17.7. Alimera Sciences, Inc.
  • 17.8. Apexian Pharmaceuticals, Inc.
  • 17.9. Bayer AG
  • 17.10. Boehringer Ingelheim International GmbH
  • 17.11. F. Hoffmann-La Roche Ltd
  • 17.12. Genentech, Inc.
  • 17.13. Glycadia Pharmaceuticals, Inc.
  • 17.14. Kodiak Sciences Inc.
  • 17.15. Kubota Vision, Inc.
  • 17.16. MingSight Pharmaceuticals, Inc.
  • 17.17. Novartis AG
  • 17.18. Ocular Therapeutix, Inc.
  • 17.19. Oxurion NV
  • 17.20. Regeneron Pharmaceuticals, Inc.
  • 17.21. Regenxbio Inc.
  • 17.22. RemeGen Co., Ltd.
  • 17.23. Santen Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FARICIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FARICIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FARICIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEXAMETHASONE IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEXAMETHASONE IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEXAMETHASONE IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FLUOCINOLONE IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FLUOCINOLONE IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FLUOCINOLONE IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TRIAMCINOLONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TRIAMCINOLONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FOCAL/GRID PHOTOCOAGULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FOCAL/GRID PHOTOCOAGULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY FOCAL/GRID PHOTOCOAGULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PANRETINAL PHOTOCOAGULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PANRETINAL PHOTOCOAGULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PANRETINAL PHOTOCOAGULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY EYE DROPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY EYE DROPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 203. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 207. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 208. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 209. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 236. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 237. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 240. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 241. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 242. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 247. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 248. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 251. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 252. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 253. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)

TABLE 276.